Verrica Pharmaceuticals Inc (1NE F) stock market data APIs
€0.4849
-0.05(-10.3%)
as of June 30, 2025
Try our APIs with
free plan!
Verrica Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Prev. Close
0.4849
Open
0.4391
High
0.4849
Low
0.4391
52 wk Range
0.3234-7.945
Market Cap
40 789 K
Shares Outstanding
92 491 K
Revenue
7 179 K
EPS
-0.43
Beta
1.758
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verrica Pharmaceuticals Inc data using free add-ons & libraries
Get Verrica Pharmaceuticals Inc Fundamental Data
Verrica Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 7 179 K
- EBITDA: -53 734 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-10
- EPS/Forecast: -0.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verrica Pharmaceuticals Inc News
New
Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
Verrica Pharmaceuticals Inc. Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance WE...
Verrica Pharmaceuticals Chairman of the Board Acquires 1.3% More Stock
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) shareholders (or potential shareholders) will be happy to see that the Chairman of the Board, Paul Manning, recently bought a whopping US$1.0m worth of stock...
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
Verrica Pharmaceuticals Inc. – Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones – ...
Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday
The company's shares dropped because it will require financing to help launch its first marketed product.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
